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1. INTRODUCTION
Patients  with  ischemic  heart  disease  fall  into  two large  groups: 
patients with chronic coronary artery disease (CAD) who most commonly 
present with stable angina  and patients with acute coronary syndromes 
(ACSs)1,2. The latter group, in turn, is composed of patients with acute 
myocardial infarction (MI) with ST-segment elevation on their presenting 
electrocardiogram  and those with unstable angina and non-ST-segment 
elevation MI (UA/NSTEMI)3,4.
The early (30-day) mortality rate from AMI is ~30%, with more 
than half of these deaths occurring before the stricken individual reaches 
the hospital5.  Although the mortality rate after admission for AMI has 
declined by ~30% over the past two decades, approximately 1 of every 
25 patients who survives the initial hospitalization dies in the first year 
after AMI. Mortality is approximately fourfold higher in elderly patients 
(over age 75) compared with younger patients6,7.
Early  Complications  of  STEMI include  Ventricular  dysfunction, 
Cardiogenic shock8,9, Infarction related arrhythmias, thromboembolism , 
Left  ventricular  aneurysm10,  papillary  muscle  rupture,  ventricular  free 
wall rupture and ventricular septal rupture13,14.
In  clinical  practice,  there  are  many  scoring  systems15 based  on 
either clinical features or ECG changes  are used for predicting the early 
complications  following  STEMI.  KILLIP’s  classification18,  TIMI 
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scoring system16,17  and PREDICT scoring system are few among them. 
There are certain biochemical substances are also found to be elevated 
in  complicated  cases  of  STEMI  like  HsCRP,  NT-BNP19 by  various 
studies. Serum uric acid is one among them which is being under study 
in acute coronary syndromes as a prognostic predictor 20-25. My study is 
mainly  intended  to  find  whether  there  is  an  association  between 
hyperuricemia and early complications of STEMI or not.
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2.AIMS  AND OBJECTIVES
The Aims and Objectives of this study are:
1. To know the prevalence of Hyperuricemia in STEMI patients.
2. To  know the  significance  of  association  of  Hyperuricemia  with 
other  cardio vascular risk factors.
3. To know the association of Hyperuricemia with infarction pattern.
4. To know  the significance of association of Hyperuricemia with 
early complications of STEMI.
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3.REVIEW OF  LITERATURE
Acute myocardial infarction with ST-segment elevation (STEMI) 
remains a major global public health issue. Despite advances in therapy, 
patients remain at risk for death, repeat myocardial  infarction (MI), shock 
and  heart  failure  (HF).  Novel  markers that  predict  those  at  risk  are 
needed. 
Study conducted by Justin A Ezekowitz and  Jeffery A Bakal et al 
at University of Alberta, Edmonton, Canada among  903 STEMI patients 
revealed  that   NT-proBNP  performed  early  and  at  24  hrs provides 
important  prognostic  information  for  predicting  negative outcomes  i.e. 
shock, heart failure and death19. 
A  wide  variety  of  nonlipid  biochemical  markers  have  been 
suggested in an effort to better identify those individuals at an increased 
for  complications  of  myocardial  infarction.,  including  markers  of 
fibrinolytic  and hemostatic  function (tissue type plasminogen activator 
antigen,  plasminogen  activator  inhibitor-1,  fibrinogen,      von 
Willibrand,     D-dimer,    thrombin-antithrombin III complex, and factors 
V, VII, and VIII), homocysteine,   and   markers  of  inflammation   (high-
sensitivity  C-reactive  protein  (hsCRP),  serum amyloid  A,  interleukins, 
adhesion molecules, heat shock proteins, and matrix metalloproteases,and 
Serum uric acid26.
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SERUM URIC ACID
An association between elevated levels of circulating uric acid and 
increased  incidence  of  morbidity  and  mortality  in  acute  coronary 
syndromes  has  been  documented  for  many  years.  Since  then,  several 
studies are coming up supporting  this issue. 
Biochemistry and  Physiology:
In  humans,  uric  acid  (2,  6,  8  – trihydroxy purine)  is  the major 
product  of  the  catabolism  of  the  purine  nucleosides,  adenosine  and 
guanosine. Purines from catabolism of dietary nucleic acid are converted 
to uric acid directly27. 
The bulk of purine excreted as uric acid arise from  degradation of 
endogenous  nucleic  acids.  The  daily  synthesis  rate  of  uric  acid  is 
approximately  400mg;  dietary  sources contributes  another  300mg27.  In 
men consuming a purine - free diet, the total body pool of exchangeable 
urate is estimated as 1200 mg. 
In women it is estimated to be 600mg. By contrast patients with 
gouty arthritis  and tissue deposition of  urate  may have urate  pools  as 
large as 18000 to 30000 mg28.  Overproduction of uric acid may result 
from increased synthesis of purine precursors.
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Synthetic Pathway of Uric acid:
Fig 3.1 Synthetic Pathway of Uric Acid
Fate of Uric acid:
 Lower  primates  and  mammals  other  than  humans  carry  purine 
metabolism one step further  with the formation of  allantoin from uric 
acid,  a  step  mediated  by  uricase  oxidoreductase29.  In  humans, 
approximately 75% of uric acid excreted is lost in the urine most of the 
remainder is secreted into the gastrointestinal tract, where it is degraded 
to attention and other compounds by bacterial enzymes31,32.
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Fig 3.2 Fate of Uric Acid
Renal handling of uric acid30:
1.Glomerular  filtration  of  virtually  all  the  uric  acid  in  capillary 
plasma entering the glomerulus.
2.Re-absorption in the proximal convoluted tubule of about 98% to 
100% of filtered uric acid.
3.Subsequent  secretion of  uric  acid into  the lumen in the  distal 
portion of the proximal tubule.
4.Further re-absorption in the distal tubule.
 The net urinary excretion of uric acid is 6% to 12% of the amount 
filtered.
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Major Causes of Hyperuricemia:
Increased formation Primary:
 Idiopathic
 Inherited Metabolic disorder
Secondary:
 Excess dietary purine intake
 Increased  nucleic  acid 
turnover  (leukemia, 
myeloma,  radiotherapy, 
chemotherapy, trauma)
 Psoriasis
 Altered ATP metabolism
 Tissue hypoxia
 Pre- eclampsia
 Alcohol
Decreased Excretion Primary:
 Idiopathic
Secondary:
 Acute/Chronic  kidney 
disease
 Increased renal re-absorption
 Reduced secretion
 Lead poisoning
 Preeclampsia
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 Low dose salicylates
 Thiazide diuretics
 Trisomy 21
Pathophysiology of  raised  SUA in Coronary artery diseases:
There  is  increasing  evidence  that  strongly  supports  a  direct 
pathophysiological  role  for  the  metabolic  pathway  leading  to  UA 
production in the failing circulation. In this regard, the two terminal steps 
in urate production are catalyzed by XO, which also produces a molecule 
of  superoxide  for  each  reaction5  XO is  the  product  of  the  xanthine 
oxidoreductase  gene  that  encodes  XDH,  an  150  Kda  protein,  which 
functions  as  a  homodimer.  XDH  is  converted  to  XO  by  proteolytic 
cleavage or sulfhydryl modification33.
The elevation  in serum UA may reflect  increased XO pathway 
activity and in turn the generation of superoxide and  resultant oxidative 
stress via the XO system. XO is upregulated  within the heart in both 
experimental and human heart failure34. Much had previously been made 
of  the  difficulty  in  identifying  XO  within  the  hearts  of  certain 
mammalian species, including humans; nevertheless, it is clear that XO, 
which  is  produced  in  highest  abundance  in  the  liver  and  gut,  may 
circulate in the blood and adhere to endothelium in distant sites35.
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 Moreover,  XO is  expressed in  cardiac  myocytes,  as  shown by 
immunohistochemistry and may participate in intracrine signaling.From a 
functional standpoint, XO activity participates in both Mechanoenergetic 
uncoupling  and  vascular  dysfunction  in  the  failing  circulation. 
Mechanoenergetic  uncoupling  is  the  process  whereby  cardiac  energy 
consumption  remains  the  same  or  increases  while  cardiac  work  falls 
dramatically, and is increasingly being perceived as a potential key lesion 
in the failing heart. Inhibition of XO with allopurinol restores depressed 
myocardial energetics toward normal, and this effect can be mimicked by 
the antioxidant ascorbate. 
Furthermore,  several  recent  studies  have  demonstrated  that  XO 
inhibition improves  endothelial  dysfunction in  patients  with congestive 
heart  failure  in  association  with  reduction  in  circulating  markers  of 
oxidative stress, thereby providing evidence that XO inhibition reduces 
oxidant generation36.
Beyond XO activity, recent experimental studies suggest that UA 
itself may have a role in cardiovascular and renal pathophysiology. This 
might seem surprising,  as UA can function as an antioxidant,  both by 
itself  and  by  promoting  superoxide  dismutase  activity  and  might 
therefore  be  considered  potentially  protective.  However,  UA potently 
stimulates  vascular  smooth  muscle  cell  proliferation  in  vitro,an  effect 
mediated  by  stimulation  of  mitogen-activated  protein   kinases, 
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cyclooxygenase-2, and platelet-derived growth factor37. 
Furthermore, rats with mild experimentally induced hyperuricemia 
develop  intrarenal  vascular  disease  with  increased  renin  expression, 
systemic and glomerular hypertension, and renal injury in the absence of 
intrarenal crystal deposition.These hemodynamic and structural changes 
can be prevented if UA elevation is prevented by allopurinol38.
Interaction of Xanthine Oxidase and Uric Acid With Nitric  Oxide 
Pathways:
Both XO activity and UA may also affect cardiac and renal nitric 
oxide  signaling,  which  exerts  key  cardiac  and  vascular  effects39.  The 
impact  of  XO  inhibition  to  restore  depressed  myocardial  energetics 
requires intact NO pathway activity.UA may also impair NO production 
directly, as suggested by the finding that UA infusion into forearm veins 
of humans attenuates acetylcholine-stimulated vasodilation40.
Likewise, the hypertension associated with hyperuricemia in rats is 
associated with reduced expression of macula densa neuronal nitric oxide 
synthase (NOS) and can be partially reversed by the NOS substrate L-
arginine19. This finding has interesting implications for cardiac function, 
as  neuronal  NOS  plays  a  key  role  in  modulating  cardiac  excitation-
contraction  coupling  by  facilitating  sarcoplasmic  reticulum  calcium 
release.
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Recent data suggest that uric acid is generated locally in the vessel 
wall  by  the  action  of  xanthine  oxidase.  This  enzyme,  activated  during 
ischemia-  reperfusion  by  proteolytic  conversion  of  xanthine 
dehydrogenase,  catalyzes  the  oxidation of  xanthine,  thereby generating 
free radicals and uric acid. 
Because of the potential role of ischemia -reperfusion in vascular 
disease, the effects of uric acid on rat aortic vascular smooth muscle cell 
(VSMC)  growth  was  studied41.  Uric  acid  stimulated  VSMC  DNA 
synthesis,  as  measured  by  [3H]  thymidine  incorporation,  in  a 
concentration-dependent manner with half-maximal activity at 150  PM. 
Neither uric acid precursors (xanthine and hypoxanthine) nor antioxidants 
(ascorbic acid, glutathione,a nd a-tocopherol)  were mitogenic for VSMC. 
Uric  acid  was  mitogenic  for  VSMC  but  not  for  fibroblasts  or  renal 
epithelial cells. The time course for uric acid stimulation of VSMC growth 
was slower  than  serum,  suggesting  induction  of  an  autocrine  growth 
mechanism. 
Exposure of quiescent VSMC to uric acid stimulated accumulation 
of PDGF α-chain mRNA (>5-fold at 8 h) and secretion of   PDGF- like 
material in conditioned medium45,46. 
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Uric  acid-induced   [3H]thymidine   incorporation  was markedly 
inhibited  by incubation  with  anti-PDGF α chain  polyclonal  antibodies. 
Thus  uric  acid  stimulates  VSMC  growth  via  an  autocrine  mechanism 
involving PDGF α -chain42. 
These findings suggest that generation of uric acid during ischemia-
reperfusion  contributes  to  atherogenesis  and  intimal  proliferation 
following arterial injury.
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OTHER  BIOMARKERS
High-Sensitivity C-Reactive Protein
Tillet and Francis in 1930 described a substance that was present in 
the  sera  of  acutely  ill  patients  and  able  to  bind  the  cell  wall  C-
polysaccharide  of  Streptococcus  pneumoniae  and  agglutinate  the 
organisms. In 1941 the substance was shown to be a protein and given the 
name C-reactive protein (CRP).
CRP was subsequently shown to be an acute phase reactant and 
important  in  the  nonspecific  host  defense  against  inflammation, 
especially  infection  and  is  routinely  monitored  as  an  indication  of 
infection and autoimmune diseases using methods having detecting limits 
of 3 to 8 mg/L
Chronic  inflammation  is  an  important  component  in  the 
development  and  progression  of  atherosclerosis,  and  numerous 
epidemiological  studies  have  demonstrated  that  increased  serum CRP 
concentrations  are  positively  associated with a  risk of  future coronary 
events, such as coronary artery disease or peripheral arterial disease47. It 
has also been shown to be predictive of future events in patients with 
acute coronary syndromes and in patients with stable angina and coronary 
artery stents.
In general, those individuals with baseline hsCRP values in the top 
quartile  of  the  sample  distribution  are  2  to  3  times  more  likely  to 
experience a future vascular event than those in the bottom quartile. The 
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association between hsCRP and future vascular  events  is  linear  and is 
independent of age, smoking, hypertension, dyslipidemia, and diabetes. 
For example,  8-year follow-up data from the Physicians'  Health Study 
and the WHS showed that after adjustment for traditional risk factors, 
there was an increase in a future cardiovascular risk of 26% for men and 
33% in women for each quintile increase in baseline hsCRP48.
Since hsCRP values minimally correlate with lipid concentrations 
and lipid parameters account for <3% to 5% of the variance in hsCRP 
measurement,  the measurement of hsCRP does not replace but instead 
complements the evaluation of lipids and other classical CHD risk factors 
in primary prevention settings49.
Data  from  the  WHS  demonstrated  that  hsCRP adds  prognostic 
information not only at all levels of the risk defined by current LDL cut 
points of the NCEP but also at  all levels of the risk specified by the 
Framingham risk score algorithm.
Serum Homocysteine:
Numerous studies have suggested an association between elevated 
levels  of  circulating  homocysteine  and  various  vascular  and 
cardiovascular disorders. In addition, tHcy levels also are related to birth 
defects,  pregnancy  complications,  psychiatric  disorders,  and  mental 
impairment  in  the  elderly.  Clinically  the  measurement  of  tHcy  is 
considered important
 (1) to diagnose homocystinuria, 
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(2)   to  identify  individuals  with  ur  at  a  risk  of  developing 
cobalamin or 
      folate deficiency, and 
(3) to assess tHcy as a risk factor for cardiovascular disease (CVD) 
and 
     other disorders50.
Serum Amyloid
Serum  amyloid  protein-A  is  an  acute  phase  protein,  and  an 
apolipoprotein has often been used with hsCRP in cross sectional studies. 
It can be synergistic with hsCRP51 but is much less commonly used. At 
present, there is no standardized assay and no reference interval studies or 
consistent assay validations.
sCD40 Ligand
sCD40 ligand is a transmembrane protein related to TNF. It  has 
multiple  prothrombotic  and  proatherogenic  effects.  What  is  usually 
measured is the soluble form of the receptor, which has been shown to be 
a predictor of events after acute presentations52. At present,  there is no 
standardized assay and no reference intervals studies or consistent assay 
validations.
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Cytokines
There are a variety of stimulatory and inhibitory interleukins (TNF, 
IL-1,  IL-6,  IL-8,  IL-12,  IL-18)  that  are  thought  to  help  mediate  the 
elaboration  of  CRP and  the  development  of  atherosclerosis  and  acute 
events.  These  cytokines  either  stimulate  or  inhibit  leukocytes,  often 
through  T-cell  mediated  processes  ,  which  are  indigenous  to 
atherogenesis53.  In  some studies,  IL-6 is  more prognostic than hsCRP. 
These  cytokines  often  have  inhibitors  and/or  binding  proteins  that 
modulate their effects. At present, there are no standardized assays and no 
normal range studies or consistent assay validations.
Myeloperoxidase
Myeloperoxidase is released when neutrophils aggregate and thus 
may indicate an active inflammatory response in blood vessels.  It  has 
been shown to be elevated chronically when chronic CAD is present54. It 
is increased when patients present with ACS. Initial  prognostic studies 
were encouraging but were done without adequate consideration of other 
analytes and specifically cardiac troponin. Accordingly, additional studies 
are needed. At present, there is no standardized assay and no reference 
interval studies or consistent assay validations.
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Phospholipase A2
Phospholipase A2 (Lp PLA2) is a phospholipase associated with 
LDL and is  thought  to  be  an inflammatory  marker.  It  was  previously 
known  as  platelet  activating  factor  acetyl  hydrolase  (PAF).  It  is 
synthesized  by  monocytes  and  lymphocytes.  It  is  thought  to  cleave 
oxidized lipids to induce lipid fragments that are more atherogenic and 
that increase endothelial adhesion. There is an FDA approved assay for 
this analyte with obligatory normal intervals.  It  has been shown to be 
predictive of events in a primary prevention cohort even when hsCRP is 
present in the model, suggesting it measures something different from the 
acute phase reactants associated with hsCRP55.
Pregnancy Associated Plasma Protein A
Pregnancy  associated  plasma  protein  A  (PAPP-A)  is  a 
metalloproteinase  expressed  when  IGF  is  freed  from  inhibition.  It  is 
thought to be expressed in plaques that may be prone to rupture.  The 
literature  in  this  regard  is  mixed  at  present  concerning  its  use56.  At 
present, there is no standardized assay and no reference interval studies or 
consistent assay validations.
Oxidized LDL:
Oxidized LDL has been attributed a key role in the development of 
atherosclerosis. Several methods have been used to measure it, but they 
give  potentially  different  data.  Some have  correlated  malondialdehyde 
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LDL with  the  development  of  atherosclerosis  and  short-term events57. 
Direct identification with antibodies suggests that oxidized LDL may be 
released from vessels and co-localize with Lp(a) after acute events.
Placental Growth Factor
Placental growth factor is an angiogenic factor related to vascular 
endothelial growth factor (VEGF), which stimulates smooth muscle cells 
and macrophages. It  also increases TNF and MCP-1. There is a novel 
assay  for  this  analyte  that  is  thought  to  provide  additional  prognostic 
information on patients who present with ACS.58 At present, there is no 
standardized assay and no reference interval studies or consistent assay 
validations.
Matrix Metalloproteinases
Matrix metalloproteinases (MMP) can degrade the collagen matrix 
in either coronary artery or myocardium. They are integral to remodeling 
of the coronary artery and/or the heart after acute events. Elaboration of 
MMP 9, a gelatinase, is thought to be important in plaque destabilization 
and thus some have tried to measure it  as a prognostic  index59.  Other 
MMPs participate in the elaboration of extracellular matrix in the heart. 
Many  of  the  MMPs also  have  inhibitors  (TIMPs)  that  modulate  their 
effects. At present, there are no standardized assays and no normal range 
studies or consistent assay validations.
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Monocyte Chemotactic Protein 
Monocyte  chemotactic  protein  (MCP-1)  is  a  chemokine  that  is 
thought  to  be  responsible  for  the  recruitment  of  monocytes  into 
atherosclerotic plaque. It has been reported to be elevated in patients with 
ACS and to have long-term predictive value60. However, at present, there 
is no standardized assay and no reference interval studies or consistent 
assay validations.
Tumor Necrosis Factor Alpha
Tumor necrosis factor alpha (TNFa) is an inflammatory cytokine 
and interleukin that is involved in the genesis of sepsis, arthritis, and a 
variety of other inflammatory states . It also has hemodynamic effects and 
reduces ventricular performance. It is also a common signaling molecule. 
Assays for it or its receptor have been developed, but the failure of recent 
therapeutic trials has led to concern about how to properly interpret the 
high levels seen in patients with CHF and coronary heart disease61.  At 
present, there are no standardized assays and no reference interval studies 
or consistent assay validations.
Tissue Plasminogen Activator Antigen
Tissue  plasminogen activator  antigen (t-PA antigen and activity) 
and  plasminogen  activator  inhibitor  1  (PAH).  t-PA  is  the  body's 
physiological fibrinolytic activator. PAI-1 is its endogenous inhibitor and 
binds to t-PA. Inhibition of fibrinolysis has been suggested to be a reason 
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for  recurrent  infarction  and  the  fact  that  maximal  inhibition  usually 
occurs in the early morning hours a reason for the circadian variability of 
AMI62.  It  may  also  be  the  reason  why  diabetics  have  such  unstable 
disease since the growth factor properties of insulin stimulate increases in 
PAI-1.  An accurate assessment of this  system includes both and some 
assessment of the bound compared with free levels.
Secreted Platelet Granular Substances
Both platelet factor 4 (PF4) and beta thromboglobulin (BTG) are 
secreted when platelets aggregate. PF4 has a short half-life, is released by 
heparin, and is the cause of the antibodies that result in heparin-induced 
thrombocytopenia. BTG is not released by heparin and has a longer half-
life. Both markers have been used to assess platelet aggregation63. BTG is 
by far the most reliable. At present, there are no standardized assays and 
no reference interval studies or consistent assay validations.
Isoprostanes
Isoprostanes are the end breakdown products of lipid peroxidation, 
and urinary levels have been used to assess the level of oxidative stress64. 
It is thought that oxidation of LDL is essential for the development of 
atherosclerosis  and  that  HDL  and  other  antioxidants  work  by 
antagonizing this oxidative stress.  Urinary isoprostanes give one some 
summary  assessment  of  this  critical  process.  The  most  common  ones 
measured are F2-isoprostanes, but there are a large number of potential 
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ones to measure. It does appear that they will eventually be helpful in 
assessing oxidative stress.
Urinary Thromboxane
Urinary  thromboxane is  the end metabolite  of  thromboxane A2, 
which is a measure of platelet aggregation. Urinary levels are elevated in 
patients  with  unstable  coronary  disease  in  keeping  with  the  known 
participation of  platelets in the pathogenesis  of CAD. It  is  difficult  to 
measure, and collecting urine in acute situation is at times problematic.
Adhesion Molecules
Adhesion  molecules  are  a  wide  variety  of  molecules  that  can 
potentially  be  measured  as  a  way  of  assessing  the  adherence  of 
leukocytes and/or platelets or other adhesive proteins to the endothelial 
matrix65. Some are receptors. Some of the examples include PECAM-1 
(platelet-endothelial  adhesion  molecule  1),  P-selectin,  e-selectin,  and 
VCAM-1 (vascular cell adhesion molecule 1). At times, the receptor itself 
is  measured but often it  is  a soluble  portion that  circulates that  is  the 
ligand.  At  present,  there  are  no  standardized  assays  and  no  reference 
interval studies or consistent assay validations..
Ischemia Modified Albumin
Ischemia  modified  albumin  (IMA),  measured  by  the  albumin 
cobalt  binding  test,  has  been  approved  by  the  FDA for  its  negative 
predictive  value  in  concert  with  a  normal  ECG and a  normal  cardiac 
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troponin.  This  test  relies  on  changes  in  the  binding  of  cobalt  to  the 
albumin  molecule  when  ischemia  is  present66.  It  requires  additional 
validation of the meaning of a positive test before clinical use for ruling 
in ischemia.
Choline
Choline is released after stimulation by phospholipase D and has 
been touted as a test of prognosis in patients with chest discomfort.67 At 
present, there is no standardized assay and no reference interval studies or 
consistent assay validations.
Unbound Free Fatty Acid
Unbound free fatty acid (uFFA) has also been touted as a marker of 
ischemia. Most fatty acid is bound and ischemia is thought to increase the 
small unbound fraction. Initial studies have reported mixed results68. At 
present, there is no standardized assay and no reference interval studies or 
consistent assay validations.
Nourin
Nourin I is a small protein released rapidly by "stressed myocytes." 
It  induces changes in a variety of inflammatory cytokines and attracts 
neutrophils. Preliminary studies have been done attempting to validate its 
use69. At present, there is no standardized assay and-no reference interval 
studies or consistent assay validations.
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4. MATERIALS AND METHODS
Study design:
This is a cross-sectional study.
 Place of study: 
This  study  was  carried  out  in  the  Department  of  Medicine, 
Intensive Cardiac  Care Unit, Tirunelveli Medical College Hospital.
Study population:
 100 patients of STEMI who got admitted serially in ICCU. 
Inclusion criteria:
1. Cases  with  STEMI  who  fulfilled  the  pre-requisites  for 
thrombolysis and thrombolysed with streptokinase. 
2. Both failed and successful thromolysed cases were included.
Exclusion criteria:
Patients with STEMI,
1. Not  thrombolysed   because  of  late  presentation  or  patients 
having contra-indication for streptokinase use.
2. With renal failure
3. On drugs like diuretics, pyrazinamide
Study method:
This study was approved by the Ethical Committee of our institute. 
Patients   were selected for  study according to the inclusion and 
exclusion criteria, mentioned above . Detailed history regarding smoking, 
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alcoholism, diabetes mellitus, hypertension, Drug intake  was enquired. 
Vital  signs,  waist/Hip  ratio,  15  lead-ECG findings  were  noted.  Blood 
sugar  values,  Fasting  lipid profile  and  Fasting  Serum uric  acid  were 
noted. After thrombolysis patients were followed up till  they leave the 
hospital.  During  the  hospital  stay  they  were  closely  monitored  for 
development  of  complications  like  Heart  failure,  Cardiogenic  shock, 
Arrhythmias, Thromboembolism  and sudden cardiac death. 
Diagnosis of STEMI was made by:
Presence of at least two of the following criteria:
1. Prolonged chest discomfort or angina equivalent (30 min)
2. Presence of  more than or equal to 1 mm ST elevation in two 
consecutive  leads.
3. Presence of elevated cardiac biomarkers.
ECG was interpreted as  ST elevation in:
L1,aVL,V1-V6 : Extensive anterior 
L1,aVL : High lateral
L1,aVL,V5-6 : Antero-Lateral
V1-V4 : Anteroseptal
LII,LIII,aVF : Inferior
LII,LIII,aVF,rV4 : Inferior+Right ventricular
LII,LIII,aVF,V8,V9 : Inferior+Posterior
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Diabetes mellitus:
Patients were considered as diabetic only when they were known 
diabetic on treatment or fasting blood sugar >126 mg%.
Hypertension:
Patients were considered hypertensive only when they were known 
hypertensive  on  treatment  or  Systolic  BP>140mmHg  and  Diastolic 
BP>90mg%.
Central obesity:
Waist  Hip Ratio >1  for men
Waist   Hip Ratio >0.8 for women
Dyslipidemia:
Total cholesterol > 240 mg%
LDL cholesterol > 160 mg%
HDL cholesterol < 40 mg%
Triglycerides > 200 mg%
Serum Uric acid:
• Estimated by Uricase method.
• Considered elevated if  serum level>7mg% for male, >6mg% 
for female.
All the above data were collected meticulously and entered into a 
proforma and master chart was prepared.
xxvii
5.RESULTS AND OBSERVATIONS
Statistical method:
Data were analyzed using computer based SPSS 13.0 software by 
Chi – Square test.   The p-value < 0.05 was considered as statistically 
significant.
Table 5.1:AGE & SEX DISTRIBUTION OF STUDY POPULATION
AGE No. of CasesMale Female Total
<40 10 2 12
41 – 50 18 16 34
51 – 60 20 15 35
61 – 70 7 7 14
>70 3 2 5
58 42 100
Inference (Table 5.1):
The majority (69%) of the patients are between the age  of 41-60. 
Males  constitute  58% of  study population.  Females constitute  42% of 
study population.
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Fig. 5.1 Age and Sex Distribution of the study population
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Table 5.2: Prevalence of Risk Factors
Sl. No Risk Factors No. of Cases Percentage
1 Age > 50 years 54 54%
2 Smoking 29 29%
3 Alcoholism 21 21%
4 Diabetes Mellitus 51 51%
5 Hyper tension 36 36%
6 Central Obesity 46 46%
7 Dyslipidemia 41 41%
8 Hyperuricemia 30 30%
Inference(Table5.2):
Age  >  50  years,  Diabetes  Mellitus  &Central  Obesity   are  the 
commonest  risk  factors.  Hyperuricemia  is  present  in  30%  of  study 
population.  
xxx
 Fig. 5.2 Prevalence of Risk factors
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Table 5.3: Distribution of Uric acid Values
Lower 
Value
Higher 
Value
Mean
Standard 
Deviation
Male 2.8 8.1 6.141 1.287
Female 3.0 7.3 4.3 1.4836
Overall 2.8 8.1 5.368 1.6430
 
Inference (Table 5.3):
Mean Serum uric acid level in females is  lower than males.
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Table 5.4: Association of Individual Risk Factor with Hyperuricemia
Sl. 
No
Risk Factor
Hyper
Uricemia
Risk 
Ratio
95% Confidence 
Interval
Chi - 
Square 
value
p - Value
Yes No
1 Age > 50yrs 21 33 2.616 1.052 – 6.506 4.417 0.029*
2 Smoking 10 19 1.342 0.533 – 3.381 0.391 0.346
3 Alcoholism 9 12 2.071 0.764 – 5.620 2.092 0.120
4
Diabetes 
Mellitus
21 30 3.111 1.248 – 7.753 6.191 0.011*
5
Hyper 
Tension
16 20 2.857 1.179 – 6.923 5.589 0.017*
6
Central 
Obesity
15 31 1.258 0.534 – 2.964 0.276 0.379
7 Dyslipidemia 12 29 1.156 0.394 – 2.253 0.018 0.537
Inference (Table 5.4 ):
Age  >  50yrs,  Diabetes  Mellitus  and  Hypertension  are  the 
statistically significant risk factors associated with Hyperuricemia.
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Table 5.5: Multivariate analysis of risk factors associated with 
Hyperuricemia
Variable Co efficient Std error F – test p – value
Age > 50 years 0.163 0.090 3.312 0.072
Male Sex 0.071 0.115 0.381 0.538
Smoking -0.014 0.122 0.013 0.908
Alcoholism 0.201 0.120 2.7962 0.097
Diabetes Mellitus 0.260 0.089 8.5396 0.004*
Hypertension 0.239 0.093 6.655 0.011*
Central Obesity 0.141 0.098 2.0439 0.036*
Dyslipidemia 0.031 0.099 0.098 0.753
Inference ( Table 5.5):
While  doing  the  Multivariate  analysis,  Diabetes  Mellitus  , 
Hypertension  and  Central  obesity  are  the  statistically  significant  risk 
factors associated with Hyperuricemia.
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Table 5.6: Analysis of Association of  Multiple Risk Factors& 
Hyperuricemia
No. of Risk 
Factors
Hyperuricemia
Yes No Total
5 3 1 4
4 14 9 23
3 12 16 28
2 2 31 33
1 0 11 11
Total 30 70 100
              
  Chi-square -27.551;  p-value: 0.001
Inference (Table 5.6):
The higher the number of total risk factors,  the association with 
hyperuricemia becomes very significant.
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Fig 5.3 Association of  Multiple Risk Factors& Hyperuricemia
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Table 5.7: Multiple Risk Factors & Hyperuricemia
Hyperuricemia
Risk 
Ratio
95% 
Confidence 
Interval
Chi-
square
Value
p – 
ValueYes No
Diabetes 
Mellitus
21 30 3.111 1.248 – 7.753 6.191 0.011*
Hyper Tension 16 20 2.857 1.179 – 6.923 5.589 0.017*
Age > 50yrs 21 33 2.616 1.052 – 6.506 4.417 0.029*
All the above 
factors together
8 5 4.727 1.399 –15.97 7.078 0.012*
Inference (Table 5.7):
While   multiple  risk  factors  are  present  in  a  single  patient  ,the 
probability of  Hyperuricemia significantly  rises .
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Fig 5.4 While Diabetes Mellitus, Hypertension, Age > 50 years are 
present in a single case risk of hyperuricemia increases by 50%
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Table 5.8: Association of Hyperuricemia & Infarction Pattern
Type of Infarction
Hyperuricemia
Total
Yes No
Anterior 25 32 57
Inferior 5 38 43
Total 30 70 100
Anterior =  Anterolateral, ASMI & Extensive Anterior Wall
Inferior = IWMI, IWMI + PWMI, IWMI + PWMI + RVMI &
IWMI + RVMI
Risk Ratio 95% Confidence Interval Chisquare Value p – Value
5.938 2.038 – 17.295 12.125 0.001*
Inference (Table 5.8):
Anterior wall MI is significantly associated with Hyperuricemia.
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Fig 5.5  Anterior wall infarctions are more commonly associated with 
Hyperuricemia
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Table 5.9: Pattern of Complications :(Total=32)
Sl. No Complications No. of Cases Percentage
1 Cardiogenic Shock 14 44%
2 Arrhythmias 7 22%
3
Sudden Cardiac 
Death
8 25%
4
Cerebro vascular 
accident
3 9%
5 LV Aneurysm 0 0%
6
Ventricular septal 
rupture
0 0%
7
Ventricular free wall 
rupture
0 0%
8
Papillary muscle 
rupture
0 0%
Inference(Table 5.9):
Cardiogenic shock  and arrhythmias are the common complications 
of   STEMI.  Other   complications  are  sudden  cardiac  death  and 
thromboembolism.
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Fig 5.6 Pattern of Complications
Table 5.10: Association of Infarction type & Complications
Infarction 
Type
Complications
Total PercentageYes No
Anterior 23 34 57 57%
Inferior 9 34 43 43%
Anterior =  Anterolateral, ASMI & Extensive Anterior Wall
Inferior = IWMI, IWMI + PWMI, IWMI + PWMI + RVMI &
IWMI + RVMI
xlii
Inference Table(5.10):
STEMI  involving  anterior  wall  is  significantly  associated  with 
more complications among the study population.
Fig 5.7  Anterior wall infarctions are more commonly associated with 
complications
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Table 5.11: Multiple Risk Factor & Complications
Complications
Risk 
Ratio
95% 
Confidence 
Interval
Chi-
square
Value
p - 
ValueYes No
Age > 50 25 29 4.803 1.828 – 12.621 11.026 0.001*
Hyperuricemia 17 13 4.795 1.910 – 12.038 11.984 0.001*
Diabetes 
Mellitus
21 30 2.418 1.011 – 5.787 4.028 0.036*
Dyslipidemia 18 23 2.516 1.064 – 5.947 4.524 0.026*
All the above 
factors together
7 1 18.760
2.196 – 
160.256
12.309 0.001*
Inference (Table 5.11 ):
While  multiple risk factors are present in a single patient ,the risk 
of complications significantly rises to several fold(four to five fold).
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Fig 5.8 While  Age >50, Hyperuricemia, Diabetes Mellitus and 
Dyslipidemia are present in a single case, there is a 100% raise in the 
possibility of complications. 
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Table 5.12: Association of  Risk Factors (including Hyperuricemia) 
with                                                                   Complications
SL
No
Risk Factor
Compli-
cations
Risk 
Ratio
95% 
Confidence 
Interval
Chi - 
Square 
value
p - 
Value
Yes No
1 Age > 50 25 29 4.803 1.828 – 12.621 11.026 0.001*
2 Dyslipidemia 18 23 2.516 1.064 – 5.947 4.524 0.026*
3 Smoking 9 20 1.015 0.370 – 2.382 0.017 0.546
4 Alcoholism 8 13 1.410 0.517 – 3.844 0.454 0.335
5
Diabetes 
Mellitus
21 30 2.418 1.011 – 5.787 4.028 0.036*
6 Hypertension 15 21 1.975 0.832 – 4.686 0.180 0.092
7 Central obesity 13 33 1.345 0.846 – 2.435 0.547 0.537
8 Hyperuricemia 17 13 4.795 1.910 – 12.038 11.984 0.001*
Inference (Table 5.12):
Age > 50yrs,  Diabetes Mellitus, Dyslipidemia  and Hyperuricemia 
are  the  statistically  significant  risk  factors  associated  with  the 
complications in the study population.
xlvi
Table 5.13: Multivariate analysis of risk factors for developing 
Complications
Variable Co efficient Std error F – test p – value
Age > 50 years 0.242 0.090 7.245 0.008*
Male Sex 0.176 0.114 2.4125 0.123
Smoking -0.088 0.120 0.533 0.466
Alcoholism 0.011 0.120 0.008 0.925
Diabetes Mellitus 0.113 0.092 1.528 0.219
Hypertension 0.098 0.095 1.064 0.304
Hyperuricemia 0.222 0.103 2.523 0.583
Inference(Table 5.13):
While doing the Multivariate analysis, only Age above 50 years is 
the statistically significant risk factor associated with the Complications. 
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6. DISCUSSION
In  our  study,  male  cases  constitute   58%  and  female  cases 
constitute 42%. Older age(age>50 years), Diabetes mellitus and central 
obesity  are  common risk  factors  associated  with  STEMI.  Most  of  the 
patients with hyperuricemia are having more than one cardiovascular risk 
factors.
 Several  studies21-25   demonstrated  possible  association  of 
hyperuricemia with other cardiovascular risk factors and also with higher 
morbidity and mortality from Coronary artery diseases. Few studies23 fail 
to  reveal  significant  association  between  hyperuricemia  and 
cardiovascular diseases. 
However, our study  shows statistically significant association of 
hyperuricemia   with   older  age  (Age>50years),  Diabetes  mellitus  and 
hypertension through uni-variate analysis of  cardiovascular risk factors. 
Multi-variate  analysis  reveals   statistically  significant  association  of 
hyperuricemia  with Diabetes mellitus ,hypertension and central obesity. 
In  an  Asian  study70 conducted  by  J.  Woo,  R.  Swaminathan,  C. 
Cockram, E. Lau' and A. Chan2,the association between serum uric acid 
concentration and some cardiovascular  risk factors  was examined in a 
working Hong Kong Chinese population (mean age 38 years), consisting 
of 910 men and 603 women. Positive associations were found between 
serum  uric  acid  concentration  and  body  mass  index,  waist  hip  ratio, 
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systolic  and diastolic  blood pressure,  urea,  creatinine,  protein,  glucose 
(fasting and 2 hours after 75 g oralglucose load),               2 hour insulin, 
triglycerides, and apolipoprotein B in men. In both sexes, serum uric acid 
was negatively associated with high-density lipoprotein cholesterol.
Moreover  in  our  study,  uni-variate  analysis  reveals  statistically 
significant  association  of    early  complications   of   STEMI  with 
Hyperuricemia   and  also  with  older  age(Age>50years),Diabetes 
mellitus ,Dyslipidemia . 
A large cross-sectional population-based study of epidemiological 
follow-up data from the First National Health and Nutrition Examination 
Survey71 (NHANES  I)  from  1971-1975  and  data  from  NHANES  I 
Epidemiologic Follow-up Study (NHEFS) suggested that increased serum 
uric acid levels are independently and significantly associated with risk of 
cardiovascular mortality.
 Another  Asian  study, the  Japanese  Acute  Coronary  Syndrome 
Study(JACSS)72  conducted at Kumamato university also concluded that 
serum UA level after AMI is a good predictor of mortality in patients who 
have AMI.
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7. CONCLUSIONS AND RECOMMENDATIONS
From the cross sectional study of  “Serum uric acid in 100 patients 
with STEMI”,  conducted at Intensive Coronary Care Unit of Tirunelveli 
medical college Hospital,  it is concluded that:
1. Mean Serum uric acid level is lower among females than males.
2. Hyperuricemia is statistically significantly associated with older 
age(Age>50years), Diabetes mellitus and hypertension.
3. Hyperuricemia  becomes  more  prevalent  while  multiple 
cardiovascular  risk factors are operating.
4. Hyperuricemia  is  statistically  significantly  associated  with 
Anterior wall STEMI.
5. Hyperuricemia is statistically significantly associated with early 
complications of  STEMI.
l
Recommendations:
1. Serum uric  acid level  can be used as a marker  for  assessing 
early complications of STEMI
2. However ,the measurement of Serum uric acid level  does not 
replace the evaluation of  other classical CHD risk factors but 
instead  complements  in  assessing  the  early  complications  of 
STEMI.
3. Further large scale studies are needed with longer duration of 
follow up to establish the causal relationship of  elevated Serum 
uric acid level with early complications of STEMI.
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ABBREVIATIONS
ACS - Acute Coronary Syndrome
NSTEMI - Non ST Elevation Myocardial Infarction 
STEMI - ST Elevation Myocardial Infarction 
XO - Xanthine Oxidase
XDH - Xanthine Dehydrogenase
SUA - Serum Uric Acid
VSMC - Vascular Smooth Muscle Cell
NT-BNP - N – Terminal Brain Natriuretic Peptide
NCEP - National Cholesterol Education Programme.
NOS - Nitric Oxide Synthase
NO - Nitric Acid.
PDGF - Platelet Derived Growth Factor.
tHcy - Total Homocysteine
PAF - Platelet Activating Factor 
VEGF - Vascular Endothelial Growth Factor
PECAM - 1 - Platelet Endothelial Adhesion Molecule
VCAM - 1 - Vascular Cell Adhesion Molecule 
NHANES-I - First National Health and Nutrition Examination Survey
NHEFS I - NHANES I  Epidemiologic Follow – up Study
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PROFORMA 
Name : Age: Sex: I.P.No :
Date of Admission : Date of Discharge :
Risk factors 
Smoking :
Alcoholism :
Blood sugar :
Blood pressure :
Fasting lipid profile :
Serum uric acid :
Electrocardiogram :
Complications during  hospital stay:
Yes No
liii
1. Cardiogenic shock
2. Arrhythmias
3. Sudden cardiac death
4. Thrombo embolism
5. Ventricular aneurysm
6. Ventricular septal rupture
7. Ventricular Free wall rupture
8. Papillary muscle rupture
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